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Summary
In humans, thromboxane (TX) A 2 signals through two TXA 2 receptor (TP) isoforms, termed TPα and TPβ, that diverge exclusively within their carboxyl terminal cytoplasmic domains. The amino terminal extracellular region of the TPs contains two highly conserved Asn (N)-linked glycosylation sites at Asn 4 and Asn 16 . Whilst it has been established that impairment of N-glycosylation of TPα significantly affects ligand binding/intracellular signalling, previous studies did not ascertain whether N-linked glycosylation was critical for ligand binding per se or whether it was required for the intracellular trafficking and the functional expression of TPα on the plasma membrane (PM). In the current study, we investigated the role of N-linked glycosylation in determining the functional expression of TPα, by assessment of its ligand binding, G-protein coupling and intracellular signalling properties, correlating it with the level of antigenic TPα protein expressed on the PM and/or retained intracellularly. From our data, we conclude that N-glycosylation of either Asn 4 or Introduction Thromboxane (TX) A 2 , the primary cyclooxygenase product of arachidonic acid in platelets, is a potent stimulator of platelet shape change, aggregation, secretion and a constrictor of bronchial and vascular smooth muscle (1) . Synthesis of TXA 2 is increased in a variety of cardiovascular diseases including myocardial infarction, stroke, bronchial asthma and pregnancy-induced hypertension, all of which are believed to coincide with imbalances either in the levels of TXA 2 , its synthase or its receptor (2) . TXA 2 mediates its actions through interaction with the shared endoperoxide prostaglandin (PG)H 2 /TXA 2 receptor termed TP (3), a member of the G protein coupled receptor (GPCR) superfamily. Two alternatively spliced variants of the human TP receptor, termed TPα and TPβ, exist (4, 5) . TPα and TPβ are identical for the N-terminal 328 amino acids, but differ in their carboxy-terminal domains (4, 5) .
As members of the GPCR superfamily, TPα and TPβ functionally couple to Gα q members to activate phospholipase (PL) C β , resulting in increased intracellular concentrations of diacylgycerol (DAG) and inositol 1,4,5-trisphosphate (IP 3 ) and mobilization of intracellular calcium ([Ca 2+ ] i ; 4, 5, 1, 6) . It has also been reported that TPα and TPβ may differentially activate other secondary intracellular signalling pathways; specifically, while both TPα and TPβ show similar PLC β activation in transfected Chinese hamster ovary cells, they oppositely regulate adenylyl cyclase (AC) activity (7) . More recent reports show that both TPα and TPβ are subject to differential heterologous desensitization. For instance TPα, but not TPβ, is subject to cross-desensitization by prostacyclin, mediated through direct protein kinase (PK) A phosphorylation of TPα at Ser 329 ; these latter findings led to the proposal that TPα may be the isoform physiologically relevant to TP:prostacyclin receptor (IP)-mediated vascular hemostasis (8) . Furthermore TPα, but not TPβ, is subject to prostaglandin (PG) D 2 receptor (DP)-mediated cross desensitization (9) . On the other hand, TPβ, but not TPα, is subject to both tonic and agonist-induced internalization (10, 11) . Asparagine (N)-linked glycosylation is a major co-translational modification which occurs in the highly specialised environment of the endoplasmic reticulum and the golgi apparatus, and involves the initial transient interaction of specific lectin like chaperones, such as calnexin and its soluble homologue calreticulin (12) , as well with co-chaperones which aid in protein folding and trafficking (13, 14) . In general, N-linked glycosylation is believed to play a major role in protein folding, maintaining the protein's correct conformation, aiding in intracellular trafficking, protein stability and in the cell surface expression of many glycoproteins (14) (15) (16) (17) (18) . TP receptors from a number of species contain two highly conserved N-linked glycosylation sites at Asn 4 and Asn 16 within their amino terminal domain (4,5, 19 -21) . Impairment of N-linked glycosylation of the human TPα isoform, either through treatment with the antibiotic tunicamycin (22, 23) or through site-directed mutagenesis, resulted in significantly reduced ligand binding, G protein coupling and intracellular signalling (24, 25) . However, these latter studies did not directly ascertain whether N-linked glycosylation was critical for ligand binding per se or whether it was actually required for the intracellular trafficking and surface expression of functionally active TPs on the plasma membrane.
Thus, the aim of the current study was to investigate the role of N-linked glycosylation in determining the level of functional TP expression, as determined by assessment of the ligand binding and intracellular signalling properties, correlating it with the level of antigenic TP protein expression on the plasma membrane. Thus, to this end, the ligand binding, intracellular signalling and antigenic expression of hemagglutinin (HA)-epitope tagged forms of the wild type TPα was compared to that of its N-linked glycosylation defective mutants HA:TPα N4-Q4 , HA:TPα N16-Q16 and HA:TPα N4,16-Q4, 16 .
From our data, we conclude that whilst N-linked glycosylation at either Asn 4 or Asn 16 is required for functional TPα expression, in the case of the HA:TPα N4,16-Q4,16 these effects are largely due to an accumulation of the non-glycosylated, inactive receptors within the endoplasmic reticulum (ER) and, consequently, result in a significant reduction in TP surface expression and intracellular signalling.
Materials and Methods

Materials.
U46619 was obtained from Cayman Chemical Company. G418, 1[2-(5-Carboxyozazol-2-yl)-6aminobenzofuran-5-oxy]-2-(2'-amino-5-methylphenoxy)-ethane-N,N,N',N'-tetraacetic Acid, pentaacetoxymethyl Ester (FURA2/AM), D-myo-inositol 1,4,5-trisphosphate, 3 
Plasmid construction and site-directed mutagenesis.
The plasmids pCMV:TXR, pCMV:TXR N4-Q4 , pCMV:TXR N16-Q16 and pCMV:TXR N4,N16-Q4,Q16 , encoding TPα, TPα N4-Q4 , TPα N16-Q16 , TPα N4,N16-Q4,Q16 were previously described (24) . To facilitate hemagglutinin (HA) epitope tagging, the respective cDNAs for TPα, TPα N4-Q4 , TPα N16-Q16 and TPα N4,N16-Q4,Q16 , were subcloned into the HindIII-EcoR1 site of pHM6 (Roche) to generate the plasmids pHM:TPα, pHM:TPα N4-Q4 , pHM:TPα N16-Q16 and pHM:TPα N4,N16-Q4,Q16 , respectively.
Cell Culture and Transfections
Human Embryonic Kidney (HEK) 293 cells were obtained from the American Type Culture Collection (Manassas, VA) and were cultured in minimal essential medium with Earle's salts (MEM) containing 10 % foetal bovine serum (FBS) and were maintained at 37 O C in 5 % CO 2 .
For transfections, HEK 293 cells were routinely plated in 10-cm culture dishes at a density of 2 X 10 6 cells/dish in 8 ml media approximately 48 h prior to transfection and thereafter were transfected with 10 µg pADVA (26) and 25 µg pcDNA-, pCMV-or pHM-based vectors using the calcium phosphate/DNA co-precipitation procedure essentially as previously described (27) . For transient transfections, cells were harvested 48 h post transfection. To create the HEK.TPα, HEK.TPβ, HEK.TP ∆328 , HEK.TPα N4-Q4 , HEK.TPα N16-Q16 , HEK.TPα N4,N16-Q4,Q16 cell lines stably overexpressing the HA-epitope tagged forms of TPα, TPβ or their respective variants, HEK 293 cells were transfected with 10 µg of Sca1-linearised pADVA plus 25 µg of the appropriate Pvu1-linearised pHM:TPα, pHM:TPα N4-Q4 , pHM:TPα N16-Q16 or pHM:TPα N4,N16-Q4,Q16 plasmids repectively. Fortyeight hr post transfection, G418 (0.8 mg/ml) selection was applied and after approximately 21 days, G418 resistant colonies were selected and individual pure clonal stable cell lines/isolates were examined for TP expression by evaluation of their radioligand binding properties.
Radioligand binding studies
TP radioligand binding assays were carried out at for saturation radioligand binding experiments using approximately 100 µg whole cell protein per assay essentially as previously described (27) . Alternatively, cells were fractionated into their soluble (S 100 ) or crude membrane /particulate (P 100 ) components prior to carrying out radioligand binding assays as previously described (24) . Protein determinations were carried out according to the Bradford assay (28) . In general, it was determined that there was approximately 3 fold more protein in the P 100 fraction relative to that in the S 100 fraction; hence, routinely, 75 µg and 25 µg aliquots of the appropriate P 100 and S 100 fractions, respectively, was used in the radioligand binding assays of fractionated cells. Radioligand binding data was analysed with the GraphPad Prisim V4.0 computer program (GraphPad Software Inc., San Diego, CA) to determine the K d and B max values.
Measurement of intracellular calcium ([Ca 2+ ] i ) mobilization
Measurments of intracellular calcium mobilization [Ca 2+ ] i in FURA2/AM preloaded HEK 293 stable cell lines (HEK.TPα, HEK.TPα N4-Q4 , HEK.TPα N16-Q16 , HEK.TPα N4,N16-Q4,Q16 and as controls, HEK 293), was carried out as previously described (27) . Briefly, cells were stimulated at 50 sec with 1 µM U46619 (from a 10 mM stock solution dissolved in ethanol), diluted in modified Ca 2+ /Mg 2+ -free Hank's buffered salt solution, containing 10 mM HEPES, pH7.67, 0.1 % bovine serum albumin (BSA) (HBSSHB) buffer at the appropriate concentration such that addition of 20 µl of the diluted drug/inhibitor to 2 ml of cells resulted in the correct working concentration (8) . The HBSSHB buffer alone had no effect on [Ca 2+ ] i mobilization by the TPs and thus did not affect experimental data. The 
Measurement of IP 3 levels
Intracellular IP 3 levels were measured as previously described (8, 29 (SDS-PAGE), and thereafter electroblotted onto poly-vinylidene difluoride membranes, essentially as described previously (30) . Immunoblots were either screened with the anti-Gα q (C19) specific antibody and HRP-conjugated secondary antibody or, to detect HA-tagged TP receptors, with the anti-HA-Peroxidase High Affinity 3F10 antibody followed by visualization of the immunoreactive proteins by chemiluminescence detection according to the supplier's instructions.
Immunofluorescence Microscopy
HEK.TPα, HEK.TPα N4-Q4 , HEK.TPα N16-Q16 and HEK. TPα N4,N16-Q4,Q16 and, as controls, HEK 293 cells were plated onto coverslips pre-coated for 1 min with poly-L-lysine (0.1 mg/ml) at a density of 0.5 X 10 5 cells in 60 mm cell culture dish. Following 
Results:
The role of N-linked glycosylation in determining the surface expression of TPα.
In the current study, we sought to investigate the role of N-linked glycosylation in determining the level of functional TPα expression, as determined by assessment of its ligand binding, G-protein coupling and intracellular signalling properties, correlating it with the level of antigenic and TPα N4,N16-Q4,Q16 receptors were due to an impaired ability to bind the radioligand or due to decreased receptor expression on the plasma membrane, saturation radioligand binding assays were performed on whole cells to determine relative surface expression of the TPs and on cells fractionated into their respective crude membrane (P 100 ) and soluble (S 100 ) fractions to determine relative total expression and data was correlated with their levels of antigenic TP protein expression as determined by ELISA in either non-permeabilised or permeabilised cells (Figure 1 ). Consistent with data obtained from Scatchard analyses, there was a strong correlation between the level of surface expression of TPα N4-Q4 , TPα N16-Q16 and TPα N4,N16-Q4,Q16 in the non-fractionated cells as determined by saturation radioligand binding ( Figure 1A) and ELISA in non-permeabilised cells ( Figure 1B) whereby the level of surface expression of TPα N4-Q4 , TPα N16-Q16 and TPα N4,N16-Q4,Q16 was reduced to approximately 47%, 65 % and 8.4%, respectively, relative to the wild type TPα (Figure 1A & 1B) .
Moreover, the fractionated cells displayed similar corresponding reductions in radioligand binding by their respective membrane (P 100 ) and soluble (S 100 ) fractions for each of the TPα N4-Q4 , TPα N16-Q16 and TPα N4,N16-Q4,Q16 receptors relative to TPα (Table 2; Figure 1C ) and thereby exhibited similar reductions in the total radioligand binding relative to the wild type TPα ( Figure 1C ). In terms of membrane (P 100 ) expression, some 82.4% of total radioligand binding occurred in the P 100 fraction for the TPα ( Table 2 ) while in the case of the TPα N4-Q4 and TPα N16-Q16 that figure was not substantially different with some 74% and 80.5% of the total TPα N4-Q4 and TPα N16-Q16 ligand binding occurring in their respective P 100 fractions ( Table 2 ). In the case of the TPα N4,N16-Q4,Q16 , the level of ligand binding in the P 100 fraction relative to its total ligand binding was reduced to 63.5% (Table 2 ). However, ELISA analysis of permeabilised cells indicated that the relative levels of total antigenic TP expression was not substantially different for the TPα N4-Q4 , TPα N16-Q16 and TPα N4,N16-Q4,Q16 relative to the wild type TPα indicating that impairment of N-linked glycosylation per se did not appreciably affect the overall level of TP protein expression ( Figure 1D ). Hence, there was a poor correlation between the relative levels of total TP expression as determined from radioligand binding from the fractionated cells and from ELISA of permeabilised cells (compare Figure 1C & 1D) . Figure 3K ). Moreover, co-staining with the FITC labelled antibody along with Rhodamine 6G confirmed that the majority of this receptor was retained within the ER ( Figure 3L ).
The role of N-linked glycosylation in G protein interaction and effector signalling.
Thereafter, we sought to investigate the functional requirement for N-linked glycosylation for intracellular signalling by the HA-epitope tagged wild type TPα, TPα N4-Q4 , TPα N16-Q16 , TPα N4, 16-Q4,16 receptors by analysing agonist induced intracellular second messenger generation and receptor: G protein interaction through co-immunoprecipitation studies. Functional coupling of TPα, TPα N4-Q4 , TPα N16-Q16 , TPα N4,16-Q4, 16 receptors to its primary effector PLCβ was assessed by monitoring agonist To ascertain whether the impaired coupling of TPα N4-Q4 , TPα N16-Q16 , TPα N4,16-Q4, 16 receptors to PLC activation was associated with an impaired ability to interact with the coupling G protein Gα q , HEK 293 cell lines stably over-expressing TPα and its respective N-linked glycosylation variants were transiently co-transfected with pCMV:Gα q or, as controls, with the vector pCMV5. Agonist induced receptor: G protein interactions were assessed by immunoprecipitating the respective HAtagged TP receptors using the anti-HA 101R antisera followed by screening the immunoprecipitates for co-precipitation of Gα q using the anti-Gα q antibody. Whereas non-stimulated, vehicle (HBS) treated cells showed no TPα: Gα q interaction either in the absence or presence of co-expression of Gα q , stimulation of those cells with U46619 (1 µM) for 5 min prior to immunoprecipitation of HAtagged TPα resulted in efficient co-immunoprecipitation of Gα q along with TPα (Figure 5Ai ).
Similarly, stimulation of cells stably expressing TPα N4-Q4 or TPα N16-Q16 led to an efficient agonistinduced co-immunoprecipitation of Gα q along with both TPα N4-Q4 and TPα N16-Q16 in cells overexpressing Gα q , but not in control pCMV5 transfected cells or in vehicle treated cells (Figure 5Aii and 5Aiii, respectively). On the other hand, Gα q was not efficiently co-precipitated with TPα N4,N16-Q4,Q16 irrespective of Gα q expression status or agonist stimulation (Figure 5Aiv ). In each case, the presence of HA-tagged TPα, TPα N4-Q4 , TPα N16-Q16 and TPα N4, 16-Q4,16 in the respective immunoprecipitates was confirmed by co-screening the blots with anti-HA 3F10 horseradish peroxidase-conjugated antibody ( Figure 5B ). Moreover, efficient transfection and over-expression of Gα q in the respective cell lines was confirmed by direct immunoblot analysis using the anti-Gα q antibody ( Figure 5C ).
Discussion.
The carbohydrate moieties of glycoproteins are, in general, believed to be important in facilitating protein folding, intracellular trafficking, cell surface expression and/or secretion and may also protect against proteolysis (15, 16) . In general, most glycoproteins are N-glycosylated while the importance and requirements of O-glycosylation where carbohydrates are attached to serine or threonines, remain to be elucidated (14) . During N-glycosylation, dolichol glycolipids donate the initial glucose3- surface expression (31 -37) . For example, N-glycosylation does not affect ligand binding or coupling to Gs/adenylyl cyclase by the β 2 adrenergic receptor (AR) but is required for its presentation on the plasma membrane (38) , while inhibition of N-glycosylation of the related α 1 AR has no affect in its ligand binding or membrane expression (39) . In the case of the thrombin receptor, tuncamycin inhibits thrombin binding to its receptor (40) and inhibits thrombin-induced [Ca 2+ ] i mobilization in human T-lymohoblastoid cells (41) .
N-linked glysocosylation is thought to play a somewhat divergent role in the case of the prostanoid subfamily of GPCRs. For the EP 3α subtype of the prostaglandin (PG) E 2 receptor, Nlinked glycosylation is essential in determining both its affinity and specificity for PGE 2 binding and in influencing its trafficking to the plasma membrane (42, 43) ; in contrast, N-linked glycosylation of the EP 3β subtype is required for its expression on the plasma membrane while both ligand binding and intracellular signalling are maintained (44) . The human prostacyclin receptor (IP) has also been confirmed to be glycosylated at both Asn 7 and Asn 78 (45, 46) and depending on the extent of glycosylation, it may influence membrane expression, ligand binding and intracellular of the IP.
TP receptors from a number of species contain two highly conserved N-linked glycosylation sites at Asn 4 and Asn 16 within their amino terminal domain (4, 5, 19 -21) . Walsh et al., (24) investigated the significance of N-linked glycosylation of TPα by mutating either one or both Asn 4 and Asn 16 converting them to Gln (Q) residues. While there was no significant change in the affinity (K d ) of the mutated receptors for the TP ligand SQ29,548, in each case there were substantial reductions in maximal ligand binding (B max ) relative to wild type TPα receptor (24) . In a related study, Chiang & Tai, (25) mutated the glycosylated Asn residues to corresponding hydrophobic Leu residues and reported that glycosylation at either Asn 4 or Asn 16 is absolutely required for ligand binding. However, a major limitation of these latter studies was that they did not directly ascertain whether N-linked glycosylation was critical for ligand binding per se or whether it was actually required for the intracellular trafficking and surface expression of functionally active TPs on the plasma membrane. Thus, employing HA-epitope tagged forms of the wild type TPα and its glycosylation defective TPα N4-Q4 , TPα N16-Q16 , TPα N4,N16-Q4,Q16 variants, in the current study we sought to employ a combination of ligand binding, intracellular signalling and immunochemical approaches to investigate the role of N-linked glycosylation in determining the level of functional TP expression correlating it with the level of antigenic TP protein expression on the plasma membrane.
Consistent with previous reports (24) , Scatchard analysis confirmed that there were no observed differences in the affinity (K d ) of either TPα N4-Q4 , TPα N16-Q16 or TPα N4,N16-Q4,Q16 relative to
TPα for the radioligand [ 3 H]SQ29,458 while in each case there was a highly significant reduction in their maximal ligand binding whereby the level of TPα N4-Q4 , TPα N16-Q16 and TPα N4,N16-Q4,Q16
expression was reduced to 41 %, 70 % and 8 %, respectively, relative to the wild type TPα. There was also a strong correlation between the relative levels of surface expression of TPα N4-Q4 , TPα N16-Q16 and TPα N4,N16-Q4,Q16 in non-fractionated whole cells, as determined by saturation radioligand binding, and in non-permeabilised whole cells as determined immunochemically by ELISA. While the fractionated cells displayed similar corresponding reductions in radioligand binding by their respective membrane (P 100 ) and soluble (S 100 ) fractions for each of the TPα N4-Q4 , TPα N16-Q16 and TPα N4,N16-Q4,Q16 receptors relative to TPα, ELISA analysis of permeabilised cells indicated that the relative levels of total antigenic TP expression was not substantially different for the TPα N4-Q4 , TPα N16-Q16 and TPα N4,N16-Q4,Q16 relative to TPα indicating that impairment of N-linked glycosylation per se did not appreciably affect the overall level of TP protein expression or turnover.
Western blot analysis confirmed that while the TPα N4-Q4 , TPα N16-Q16 and TPα N4,N16-Q4,Q16 were expressed at equivalent levels relative to the TPα, the majority of the antigenic TPα, TPα N4-Q4 and TPα N16-Q16 protein was expressed in their respective P 100 fractions while most of the TPα N4,N16-Q4,Q16
receptor protein expression was evident in the S 100 fraction where it appeared largely as a lower molecular mass non-glycosylated protein of 30 -46 kDa. Thereafter, immunofluorescence microscopy confirmed that similar to TPα, both TPα N4-Q4 and TPα N16-Q16 were abundantly expressed on the plasma membrane; however, under permeabilising conditions there was evidence of significantly increased retention and co-localisation of both the TPα N4-Q4 and the TPα N16-Q16 within the ER. In the case of TPα N4,N16-Q4,Q16 there was no significant expression of this non-glycosylated receptor on the plasma membrane while it was abundantly expressed and largely retained within the ER. Thus, collectively these data indicate that mutation of the N-linked glycosylation sites at Asn 4 and Asn 16 leads to retention of the partially glycosylated receptor within the ER and thereby most likely impairs chaperone mediated protein folding and trafficking of functionally active TP receptors to the plasma membrane. Whilst glycosylation at either Asn 4 (TPα N4-Q4 ) and Asn 16 (TPα N16-Q16 ) is sufficient to allow for the substantial expression of functional TPs on the plasma membrane, impairment of glycosylation of both Asn 4 and Asn 16 leads to the almost complete retention of the TPα N4,N16-Q4,Q16 within the ER.
Thereafter, we sought to investigate the functional requirement for N-linked glycosylation for intracellular signalling by analysing agonist-induced PLCβ effector coupling, through measurement of intracellular second messenger generation, correlating it with TP receptor: G protein interaction through co-immunoprecipitation studies. While stimulation of both the TPα N4-Q4 and TPα N16-Q16 each yielded significant increases in IP 3 generation and in [Ca 2+ ] i mobilization, in each case those levels were significantly reduced accounting for 62 % and 75 % of those levels generated by the TPα, respectively. In the case of the TPα N4,N16-Q4,Q16 , both agonist-induced IP 3 generation and [Ca 2+ ] i mobilization were significantly reduced and were not substantially greater than those levels generated by the control HEK 293 cells.
Thereafter, co-immunoprecipitation studies were employed to ascertain whether the impaired coupling TPα N4-Q4 , TPα N16-Q16 , TPα N4,16-Q4, 16 1.65 ± 0.21 0.41 ± 0.09 TPα N4,16-Q4, 16 0.42 ± 0.06 0.23 ± 0.03 HEK 293 cells stably over-expressing HA-tagged TPα, TPα N4-Q4 , TPα N16-Q16 or TPα N4,N16-Q4,Q16 were fractionated into their crude membrane (P 100 ) and soluble (S 100 ) fractions and it was determined that there was approximately 3 fold more protein in the P 100 relative to the S 100 fractions. Thereafter, saturation radioligand binding assays were performed using 20 nM [ 3 H]SQ29,548 (50.4 Ci/mmol) and 75 µg P 100 or 25 µg S 100 fractions, respectively. Data presented are the mean values of four independent experiments ± standard error mean (S.E.M; n = 4).
